Herein, we successfully developed a therapeutic agent to treat osteoporosis, consisting of polyaspartic acid moieties (HAB) serving as a bone‐targeting ligand and 30Kc19α‐RUNX2 fusion protein as a cell‐penetrable bone‐forming protein complex. The gene discussed is RUNX2; the disease is osteoporosis.